Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Arrowhead Pharma (ARWR)

Arrowhead Pharma (ARWR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,970,669
  • Shares Outstanding, K 105,849
  • Annual Sales, $ 138,290 K
  • Annual Income, $ -140,850 K
  • 60-Month Beta 1.37
  • Price/Sales 34.79
  • Price/Cash Flow N/A
  • Price/Book 10.15
Trade ARWR with:

Options Overview Details

View History
  • Implied Volatility 64.35% ( +2.77%)
  • Historical Volatility 51.67%
  • IV Percentile 36%
  • IV Rank 25.24%
  • IV High 110.70% on 06/16/22
  • IV Low 48.70% on 10/20/21
  • Put/Call Vol Ratio 0.08
  • Today's Volume 137
  • Volume Avg (30-Day) 300
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 18,091
  • Open Int (30-Day) 16,880

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.31
  • Number of Estimates 6
  • High Estimate 1.22
  • Low Estimate -0.72
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +49.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.87 +17.39%
on 07/12/22
48.08 -5.10%
on 08/11/22
+5.33 (+13.23%)
since 07/11/22
3-Month
26.81 +70.20%
on 06/14/22
48.08 -5.10%
on 08/11/22
+16.68 (+57.62%)
since 05/11/22
52-Week
26.81 +70.20%
on 06/14/22
84.83 -46.21%
on 11/09/21
-13.32 (-22.60%)
since 08/11/21

Most Recent Stories

More News
Arrowhead Pharmaceuticals (ARWR) Q3 2022 Earnings Call Transcript

ARWR earnings call for the period ending June 30, 2022.

ARWR : 45.63 (-2.83%)
Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2022. The company is hosting a conference call today, August 4, 2022, at 4:30...

ARWR : 45.63 (-2.83%)
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 third...

ARWR : 45.63 (-2.83%)
Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Mediwound (MDWD)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arrowhead Pharmaceuticals (ARWR – Research Report) and Mediwound (MDWD – Research Report) with bullish...

ARWR : 45.63 (-2.83%)
MDWD : 1.9500 (+2.63%)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 1, 2022, the Compensation Committee of the Company’s Board of...

ARWR : 45.63 (-2.83%)
Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in two Phase 1/2a clinical trials of ARO-MUC5AC and ARO-RAGE, the company’s investigational RNA interference...

ARWR : 45.63 (-2.83%)
B.Riley Financial Thinks Arrowhead Pharmaceuticals’ Stock is Going to Recover

B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) on June 17 and set a price target of $65.00. The company's shares closed last Friday...

ARWR : 45.63 (-2.83%)
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Takeda ( TSE:4502/NYSE:TAK ) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT)...

TAK : 14.12 (-0.70%)
ARWR : 45.63 (-2.83%)
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Takeda ( TSE:4502/NYSE:TAK ) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT)...

TAK : 14.12 (-0.70%)
ARWR : 45.63 (-2.83%)
Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

ARWR : 45.63 (-2.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes....

See More

Key Turning Points

3rd Resistance Point 50.33
2nd Resistance Point 49.20
1st Resistance Point 47.42
Last Price 45.63
1st Support Level 44.51
2nd Support Level 43.38
3rd Support Level 41.60

See More

52-Week High 84.83
Fibonacci 61.8% 62.67
Fibonacci 50% 55.82
Fibonacci 38.2% 48.97
Last Price 45.63
52-Week Low 26.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar